Back to Results

Labcorp Holdings Inc (LH)

Labcorp Holdings Inc. is a healthcare company listed on the NYSE as common stock. Through its Diagnostics Laboratories and Biopharma Laboratory Services segments, the company provides laboratory testing and related services for patients, healthcare providers, employers, managed care organizations, and life sciences clients. Its testing portfolio includes routine clinical analyses, specialty and esoteric tests, and disease-focused services across areas such as oncology, cardiovascular disease, genetics, endocrinology, infectious disease, women’s health, and other medical fields. Labcorp also provides digital pathology tools, online platforms for providers and payers, patient-facing applications for scheduling and results access, and a generative AI-enabled test selection tool. Founded in 1995, the company is headquartered in Burlington, North Carolina.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-LH
$292.82
4.2% Upside
Fair
$312.35
11.1% Upside
Fair
Great
August 28, 2026
September 11, 2026
2.88
1.0%
July 30, 2026
24.4x
2.6x
1.6x
23.081 B
29.339 B
24.0%
99.5%
5.3
25.5%
147.0%
Valuation • Fair Value

Labcorp Holdings Inc (NYSE-LH) Fair Value by Valuation Model

Compare the primary fair value estimate for Labcorp Holdings Inc (NYSE-LH) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$292.82

Estimated upside of 4.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$285.54

Discounted cash flow valuation reference.

Ben Graham Formula Value

$127.40

Classic Ben Graham valuation formula reference.

DDM Fair Value

$362.77

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$276.80

Comparable-company valuation reference.

Analyst Price Target

$312.35

Analysts imply upside of 11.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Labcorp Holdings Inc (NYSE-LH) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Labcorp Holdings Inc (NYSE-LH)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

14.144 B

Current operating scale indicator.

Revenue Forecast

14.712 B

Forward revenue estimate.

EBITDA

2.253 B

Current operating profitability reference.

EBITDA Forecast

2.555 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Labcorp Holdings Inc (NYSE-LH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Labcorp Holdings Inc (NYSE-LH)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.66

No elevated caution signal from this screen.

Altman Z-Score

5.3

Relatively strong balance-sheet zone.

FCF / Net Income

147.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Labcorp Holdings Inc (NYSE-LH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Labcorp Holdings Inc (NYSE-LH)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

September 11, 2026

Ex-Dividend Date

August 28, 2026

Dividend Yield

1.0%

Income yield reference.

Upcoming Dividend

2.88

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

25.5%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Labcorp Holdings Inc (NYSE-LH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Labcorp Holdings Inc (NYSE-LH) Stock Forecast & Technical Outlook

Review Labcorp Holdings Inc (NYSE-LH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Labcorp Holdings Inc (NYSE-LH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Labcorp Holdings Inc (NYSE-LH) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Labcorp Holdings Inc (NYSE-LH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Labcorp Holdings Inc (NYSE-LH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Labcorp Holdings Inc (NYSE-LH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Labcorp Holdings Inc (NYSE-LH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Labcorp Holdings Inc (NYSE-LH) has a Strong Buy consensus, with 12 buy, 5 hold and 0 sell recommendations in the current data set.

Buy 12
Hold 5
Sell 0
FAQ • Fast Investor Answers

Labcorp Holdings Inc (NYSE-LH) Stock FAQ

Quick answers about Labcorp Holdings Inc (NYSE-LH) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$292.82
Estimated upside 4.2%
Valuation Rating
Undervalued
Estimated upside of 4.2%
Analyst Target
$312.35
Implied upside 11.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Labcorp Holdings Inc (NYSE-LH) is $292.82. This implies an estimated upside of 4.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.2% versus the current market price.

The available analyst price target for Labcorp Holdings Inc (NYSE-LH) is $312.35. The analyst target implies estimated upside of 11.1%.

The current financial health read for Labcorp Holdings Inc (NYSE-LH) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Labcorp Holdings Inc (NYSE-LH) is July 30, 2026.

Based on the current data, dividend yield is 1.0%, upcoming dividend amount is 2.88, ex-dividend date is August 28, 2026, payment date is September 11, 2026.

The current P/E ratio listed for Labcorp Holdings Inc (NYSE-LH) is 24.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Labcorp Holdings Inc is 23.081 B.

The current enterprise value listed for Labcorp Holdings Inc is 29.339 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Labcorp Holdings Inc is NYSE-LH, and the stock is listed on NYSE.

Labcorp Holdings Inc (NYSE-LH) is listed on NYSE.

The current debt-to-total-capital ratio listed for Labcorp Holdings Inc is 24.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Labcorp Holdings Inc is 99.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NYSE View more

Unitedhealth Group (UNH) Unitedhealth Group (UNH)
CVS Health Corp (CVS) CVS Health Corp (CVS)
McKesson Corporation (MCK) McKesson Corporation (MCK)
Elevance Health Inc (ELV) Elevance Health Inc (ELV)
HCA Holdings Inc (HCA) HCA Holdings Inc (HCA)
Cigna Corp (CI) Cigna Corp (CI)
Cencora Inc (COR) Cencora Inc (COR)
Cardinal Health Inc (CAH) Cardinal Health Inc (CAH)
Humana Inc (HUM) Humana Inc (HUM)
Centene Corp (CNC) Centene Corp (CNC)
Quest Diagnostics Incorporated (DGX) Quest Diagnostics Incorporated (DGX)
Tenet Healthcare Corporation (THC) Tenet Healthcare Corporation (THC)
DaVita HealthCare Partners Inc (DVA) DaVita HealthCare Partners Inc (DVA)
Fresenius Medical Care Corporation (FMS) Fresenius Medical Care Corporation (FMS)
Molina Healthcare Inc (MOH) Molina Healthcare Inc (MOH)
Encompass Health Corp (EHC) Encompass Health Corp (EHC)
Universal Health Services Inc (UHS) Universal Health Services Inc (UHS)
Hims Hers Health Inc (HIMS) Hims Hers Health Inc (HIMS)
PACS Group Inc (PACS) PACS Group Inc (PACS)
Chemed Corp (CHE) Chemed Corp (CHE)
Hinge Health Inc (HNGE) Hinge Health Inc (HNGE)
Concentra Group Holdings Parent Inc (CON) Concentra Group Holdings Parent Inc (CON)
Brookdale Senior Living Inc (BKD) Brookdale Senior Living Inc (BKD)
National HealthCare Corporation (NHC) National HealthCare Corporation (NHC)